Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Rat (Rattus) MAP3K2 Antibodies:
anti-Human MAP3K2 Antibodies:
anti-Mouse (Murine) MAP3K2 Antibodies:
Go to our pre-filtered search.
Human Monoclonal MAP3K2 Primary Antibody for ICC, ELISA - ABIN969272
Kurada, Li, Mulherkar, Subramanian, Prasad, Prabhakar: MADD, a splice variant of IG20, is indispensable for MAPK activation and protection against apoptosis upon tumor necrosis factor-alpha treatment. in The Journal of biological chemistry 2009
Show all 2 references for 969272
Human Monoclonal MAP3K2 Primary Antibody for EIA, IF - ABIN1108129
Spathelf, Rautenbach: Anti-listerial activity and structure-activity relationships of the six major tyrocidines, cyclic decapeptides from Bacillus aneurinolyticus. in Bioorganic & medicinal chemistry 2009
Show all 2 references for 1108129
Cow (Bovine) Polyclonal MAP3K2 Primary Antibody for WB - ABIN2783679
Wissing, Jänsch, Nimtz, Dieterich, Hornberger, Kéri, Wehland, Daub: Proteomics analysis of protein kinases by target class-selective prefractionation and tandem mass spectrometry. in Molecular & cellular proteomics : MCP 2007
miR (show MLXIP Antibodies)-34c-3p may regulate triple-negative breast cancer progression by directly targeting the 3'-untranslated region of mitogen-activated protein kinase kinase kinase 2 (MAP3K2).
Study found miR (show MLXIP Antibodies)-186 expression significantly decreased in lung cancer tissues and cells and MAP3K2 expression increased in the same cancer tissues. Also, results confirmed that MAP3K2 is a target gene of miR (show MLXIP Antibodies)-186 and both expression correlated with prognosis.
SMYD3 (show SMYD3 Antibodies)-mediated methylation of MAP3K2 increases mutant K-Ras (show HRAS Antibodies)-induced activation of ERK1/2 (show MAPK1/3 Antibodies). (Review)
Restoration of miR17/20a in solid tumor cells enhances the natural killer cell antitumor activity by targeting Mekk2
HBXIP (show HBXIP Antibodies) activated ERK1/2 (show MAPK1/3 Antibodies) through up-regulating MEKK2.
MEKK2 has a novel function as a regulator of ubiquitylation-dependent paxillin (show PXN Antibodies) redistribution in breast tumour cells.
EBV microRNA BART (show BSND Antibodies) 18-5p targets MAP3K2 to facilitate persistence in vivo by inhibiting viral replication in B cells.
Inhibitors of apoptosis proteins regulate myogenic differentiation by directly suppressing MEKK2/3-MEK5 (show MAP2K5 Antibodies)-ERK5 (show MAPK7 Antibodies) signaling.
methylation of MAP3K2 by SMYD3 increases MAP kinase signalling and promotes the formation of Ras-driven carcinomas
results strongly support a role for MEKK2 as a regulator of signaling that modulates breast tumor cell spread area and migration through control of focal adhesion stability
FGF2 (show FGF2 Antibodies)/MEKK2 pathway mediates an alternative nonclassical pathway for beta-catenin (show CTNNB1 Antibodies) activation, and this pathway is a key regulator of bone formation by osteoblasts
Stk38 (show STK38 Antibodies) protein kinase (show CDK7 Antibodies) has a role in inhibiting TLR9 (show TLR9 Antibodies)-activated inflammatory responses by promoting MEKK2 ubiquitination in macrophages
MEKK2 is regulated through a phosphorylation-dependent association with 14-3-3 (show YWHAQ Antibodies), a group of adapters that modulate dimerization and association between proteins
MEKK2 signaling contributes to right ventricular hypertrophy and altered myocardial inflammatory gene expression in response to hypoxia-induced pulmonary hypertension.
MEKK2 alone can suppress T-cell TGF-beta (show TGFB1 Antibodies) responses. MEKK2 or MEKK3 (show MAP3K3 Antibodies) can cause ERK1/2 (show MAPK1/3 Antibodies) to phosphorylate SMAD2 (show SMAD2 Antibodies)/3 and suppress R-SMAD (show SMAD1 Antibodies)-dependent transcription. MEKK2 and MEKK3 (show MAP3K3 Antibodies) play overlapping roles in regulating Th-cell differentiation via TGF-beta (show TGFB1 Antibodies)
Data show that HDAC4 (show HDAC5 Antibodies) binds and promotes the deacetylation and activation of a key MAP3 kinase, MEKK2.
Data from experiments with Mekk2(-/-) mice show that MEKK2 may be required for controlling the strength of T cell receptor/CD3 (show CD3E Antibodies) signaling.
PB1 (show GPR97 Antibodies) domain mediates the association of MEKK2 and MEKK3 (show MAP3K3 Antibodies) with MEK5 (show MAP2K5 Antibodies) and that the respective PB1 (show GPR97 Antibodies) domains of these kinases are critical for regulation of the ERK5 (show MAPK7 Antibodies) pathway.
Rap1 (show TERF2IP Antibodies) and MEKK2 are critical upstream signaling molecules mediating BDNF (show BDNF Antibodies) stimulation of ERK5 (show MAPK7 Antibodies) in central nervous system neurons
The protein encoded by this gene is a member of serine/threonine protein kinase family. This kinase preferentially activates other kinases involved in the MAP kinase signaling pathway. This kinase has been shown to directly phosphorylate and activate Ikappa B kinases, and thus plays a role in NF-kappa B signaling pathway. This kinase has also been found to bind and activate protein kinase C-related kinase 2, which suggests its involvement in a regulated signaling process.
mitogen-activated protein kinase kinase kinase 2
, MAP/ERK kinase kinase 2
, MAPK/ERK kinase kinase 2
, MEK kinase 2
, MEKK 2
, mitogen activated protein kinase kinase kinase 2
, protein kinase MEKK2b